INTRODUCTION
Host genetic factors may have a critical role in the pathophysiology of many human cancers. 1 An interesting model is prostate cancer (PC). PC is the most frequently diagnosed non-skin cancer among men in economically developed countries and one of the leading causes of cancer-related death. 1 Worldwide, over 660 000 new cases are diagnosed each year, accounting for 10% of all new cancers in male subjects. 2, 3 In Europe, PC is the most common cancer diagnosed in men, followed by lung and colorectal cancers, and the third leading cause of death in men preceded by lung and colorectal cancers. [2] [3] [4] Furthermore, its incidence increases rapidly in European men over 50 years of age. 2, 3 Thus, it is becoming a serious health risk because of increased incidence in elderly people of Western countries. However, its diagnosis and treatment are still very difficult, as PC can take decades to progress to a clinically manifest disease. Evidence on its clinical features proposes PC as a latent and clinical cancer characterized by multifocal histologic patterns. Primary tumors often contain multiple, independent histologic foci, which are often genetically distinct. 1 However, PC seems to arise from selective and individual clones during its progression.
The PC phenotypic heterogeneity is potentially relevant for understanding the distinction between latent and clinical disease. It is also integral to comprehending the strong correlation between PC development/progression and age-related chronic inflammation. In addition, this phenotypic PC feature has also paved the way for research into its complex pathophysiology, as well as into the weight of interactions between genetic factors, the host life exposure to environmental factors (i.e. infectious agents and dietary carcinogens) and sex hormonal imbalances in PC onset and progression. This might facilitate the identification of potential molecular targets as PC biomarkers for early recognition of individuals at disease risk and for development of new therapeutic treatments. On the other hand, currently there is an overall consensus to consider serum prostate-specific antigen (PSA) as a nonspecific marker to diagnose PC. Over the past two decades, PSA has been considered a valuable tool for PC surveillance. However, the age-adjusted mortality rates due to PC have remained fairly constant. Furthermore, increased serum PSA levels have frequently been observed in several other disease states of the prostate gland than cancer. [5] [6] [7] As a result, intense research is being conducted to identify circulating tissue and genetic biomarkers as promising tools for PC diagnosis, staging and prognosis and for development of appropriate and personalized therapeutic treatments. Promising data from animal and human genetic studies have been obtained, leading to compelling evidence of a strong genetic role in PC development. Of special note are the findings obtained by case-control and twin studies, segregation analyses and genome-wide investigations, underlining a strong genetic susceptibility for PC and its clinical effects. [7] [8] [9] They have identified numerous candidate genes, and particularly their genetic variants, associated with PC risk. Cotemporally, they propose interactions, either additively or epistatically, among PC risk-related genes (and among their genetic variants). Interestingly, among the several genetic variants identified to be associated with PC risk, common single-nucleotide polymorphisms (SNPs) of a series of low penetrance alleles, the 'genetic modifier alleles', appear likely to have an important role in PC susceptibility. They include a very long list and a large gene number codifying different signaling pathways, including those involved in androgen action, DNA repair, carcinogen and sex steroid hormone metabolism and inflammation. 7 In addition, there is a general consensus on the potentiality of specific combinations of these variants, in appropriate environmental situations, in profoundly affecting the risk of PC development and progression.
Many of these aspects are summarized in this report by giving particular emphasis to describing the role of genetic variants in inflammatory and steroid hormone metabolism genes and their pathways. In particular, the data discussed in this review are based on expert opinion derived on the findings from studies on aging, age-related diseases and inflammation.
INFLAMMATION AND PC
It is now well ascertained that chronic inflammation contributes to several forms of human cancer. Cancers often arise as the end stage of inflammation in adults. Approximately 20% of adult cancers, from those affecting the liver, esophagus, stomach to those of the large intestine and prostate, are, indeed, attributable to chronic inflammatory conditions caused by infectious agents, chronic non-infectious, inflammatory diseases and/or other environmental factors. Thus, chronic inflammation is now regarded as an 'enabling feature' of human cancer. It seems to influence the cancer pathogenesis by (i) causing cell and DNA damage, (ii) triggering restorative cell proliferation to replace damaged cells and (iii) creating a tissue-rich microenvironment in cytokines, chemokines and growth factors that can enhance cell replication, angiogenesis and tissue repair. 7, 10 In addition, there is a complex interplay among host immune cells during neoplastic development, having both the ability to promote cancer and to limit or eliminate it. 11, 12 Inflammatory/immune cells and soluble factors have indeed been observed in all tissues and organs with tumors (i.e. liver, gastrointestinal tract, prostate, thyroid gland, pancreas, urinary bladder, pleura and others). 13 Furthermore, the signs of 'smoldering' inflammation (i.e. tissue remodeling, angiogenesis and other wound healing-like features) are also commonly used by pathologists as morphologic cues of invasive cancer.
14 Recent evidence demonstrates that these stromal processes have a fundamental role in cancer development and progression, and, at least in some cases, may predict the clinical behavior of a cancer better than the characteristics of the neoplastic cells themselves. 11, 12 However, the critical role of inflammatory cells in cancers has been recognized only recently. In addition, oncogenes seem to be involved in targeting proinflammatory pathways directly or indirectly. For example, Ras activates the transcription of the inflammatory cytokine interleukin-8 (IL-8), 15 whereas c-myc and bcl-2 inhibit apoptosis leading to necrotic tumor cell death and release of damageassociated molecular pattern molecules. 16 In both circumstances, the resulting host response is inflammation, which promotes tumor invasion and growth. 10 Furthermore, several pathways linking inflammation and cancer have been identified: an intrinsic one, driven by genetic events that cause neoplasia, and an extrinsic one, driven by inflammatory conditions that predispose to cancer. 10 Key orchestrators at the intersection between intrinsic and extrinsic pathways include transcription factors, particularly nuclear factor-kB (NF-kB). NF-kB is a cytoplasmatic sensor constituted by a protein complex (Rel family proteins: RelA/p65, c-Rel and RelB and NF-kB components: p50/p105 and p52/p100) and inhibited commonly by binding to IkB proteins (IkBa, IkBb, IkBg, IkBd, IkBe, IkBz and Bcl3). It modulates the inflammatory response by mediating the gene expression of a large array of proinflammatory genes, and consequently the release of soluble mediators (cytokines, chemokines) and cellular components (e.g. tumor-associated macrophages), promoting cancerogenesis. 17 NF-kB assists in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immunity and alters responses to hormones and chemotherapeutic agents. Emerging evidence suggests that its continual activation and the consequent persistent inflammation promote genetic instability. 17 Thus, cancer-related inflammation represents a target for innovative diagnostic and therapeutic strategies. 18 As a result, particular attention is being focused on potential stimuli involved in prostatic inflammation and in identifying PC immune biology, inflammatory pathways and inflammatory mediators implicated in PC risk and development. On the other hand, this recent interest is based on the current hypothesis on prostate carcinogenesis excellently evidenced by De Marzo et al. 19 This hypothesis sustains that genetic factors and the exposure to environmental factors, such as infectious agents (i.e. sexually transmitted organisms such as Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and Treponema pallidum, and non-sexually transmitted bacteria such as Propionibacterium acnes and those known to cause acute and chronic bacterial prostatitis, primarily Gram-negative organisms such as Escherichia coli, and viruses such as Papillomavirus, Human Herpes simplex type-2, Cytomegalovirus), dietary carcinogens, hormonal imbalances, physical trauma and urine reflux cause injury of the prostate and lead to the development of recurrent and chronic inflammation. 19 Chronic inflammation results in the formation of typical risk factor lesions in epithelial prostate cells, called 'proliferative inflammatory atrophy' (PIA). These lesions occur predominantly at the periphery of the prostate gland, where PC typically arises. 19, 20 Many of the PIA areas may show morphologic transitions in prostatic intraepithelial neoplasia (PIN) lesions considered putative PC precursors by De Marzo et al. 19 ( Figure 1 ). These morphologic transitions from PIA to PIN and PC have been confirmed by recent data from other research groups. Among these, the findings of Wang et al. 21 are remarkable. By examining serial sections of whole-mount prostates from 50 cases, they observed that 17% of PIN lesions were found to be in the morphologic process of merging with PIA in 70% of the prostates examined. Furthermore, instances of PIA directly merging with cancer were identified in In addition, an increasing number of recent histologic investigations confirm that PC tissues are commonly characterized by chronic inflammation. Lymphocytes, macrophages and, less frequently, other plasma cells and eosinophils were commonly observed in the tissue samples. 19, 20, 22 In particular, they showed increased infiltration of CD45 þ cells in PIA lesions (all leukocytes express CD45 and non-leukocytes do not) with 70-80% of CD3 þ T lymphocytes and10-15% of CD19 þ or CD20 þ B cells. Macrophage numbers also seemed increased in PIA lesions. In phenotypical terms, a reversed CD8:CD4 ratio seems to characterize the T cells. In terms of T-cell receptors, 90% of the cells appear to be 'standard' ab T cells and 1% appear to be gd T cells. Class II major histocompatability antigen indicating the T cells 'activated' by antigen signaling has been observed to be expressed on approximately 40% of the CD3 þ T cells. Many of these T cells show CD45RO, indicating 'antigen-experienced' T cells. None of the T cells in the normal prostate epithelium show evidence of activation or of being antigen-experienced T cells. In addition, CD4 þ T-cell responses in PIA, PIN and PC samples, divided into several different types and classified according to their cytokine profile (i.e. T helper type 1 (Th1) cells produce interferon-g and tumor necrosis factor-a (TNFa), whereas Th2 cells produce IL-4, IL-5 and IL-13), have been defined as complex. In benign prostate hyperplasia and PC tissues, both Th0 (T cells that do not express any of the indicated cytokines) and Th1 cells have been observed. 19, 20 However, some features of a Th2 response have also been detected. 19, 20 In addition, regulatory T cells, able to suppress adaptive T-cell responses and autoimmunity, characterized by the expression of CD25 and FOXP3, their typical transcription factor and secretion of transforming growth factor-b (TGF-b), have also been identified in PIA, PIN and PC. 19, 20 Recently, Miller et al. 23 evidenced CD4 þ and CD25 þ T cells, with properties of regulatory T cells including the expression of the FOXP3 protein, in increased numbers in clinically localized PC tissues compard with normal prostate tissues. Th17 cells, a new subset of CD4 effector T cells, which develop through distinct cytokine signals (especially IL-23) with respect to those involved in Th1 and Th2 responses, and release IL-17 cytokine, have also been identified in PIA, PIN and PC tissue samples. 20 In particular, it has been evidenced that activated T cells in benign prostate hyperplasia and PC tissues express high levels of IL-17. 20 However, further investigations are needed to fully elucidate the phenotypic and biologic properties of all T-cell subsets in prostate tissues. This may allow one to understand the significance of clonotypical cell-mediated immunity in prostate carcinogenesis. Methods such as the quantitative image analysis of immunohistochemically stained inflammatory cell subsets and flow cytometry for these subsets using tissues isolated from histologically defined areas might be crucial to obtain such data.
During PC development and progression, the role of innate/ inflammatory immune cells is also crucial, as demonstrated by several recent histopathologic investigations. Paradoxically, it has been demonstrated that activation of the innate immune response (particularly through the NF-kB pathway) through Toll-like receptor (TLR)4-mediated recognition of pathogen-associated molecular patterns or damage-associated molecular pattern molecules can promote tumor development. This results in a milieu rich with inflammatory mediators. 20, 24 Thus, inflammatory mediators released through the NF-kB-TLR4 pathway may contribute through their physiologic functions to the development and progression of cancer, such as PC. Specifically, IL-1, IL-6, IL-8 and TGF-b released by immune cells and tumor cells promote angiogenesis, tumor growth and the differentiation of Th1, Th17 and regulatory T cells. 25 Accordingly, recent studies demonstrate that TLR4 and IL-1 receptor-associated kinase sequence polymorphisms are important risk factors for PC. 7, 26 Other studies evidence that the MyD88-dependent signaling pathway also have a critical role in the production of IL-6 and in both spontaneous and carcinogen-induced development of tumors. 26, 27 Taken together, these studies indicate that TLR4-mediated inflammation induced from bacterial and viral infection or from other endogenous and exogenous agents can promote the development of cancers, such as PC. Thus, the blockade of signaling pathways required for inflammation or the induction of proinflammatory mediators might decrease the risk of tumorigenesis. Several agonists have been developed as anticancer drugs. However, optimal antitumor immunity requires robust enhancement of the effector T-cell response induced by tumor-specific antigenic peptides and control or elimination of regulatory T cellsuppressive function. Accordingly, the combination of peptidebased vaccines with TLR agonists may greatly improve the therapeutic potential of cancer vaccines. 21, 24 As discussed, a number of separate research lines support the strong role of inflammation in prostatic carcinogenesis and tumor progression. These lines involve epidemiologic, genetic, histopathologic, molecular pathology and animal studies. Of particular attention are the data suggesting the crucial role of genetic factors and environmental factors (e.g., lifestyle or microbial infection and underlying subclinical prostatitis) in the induction of a chronic inflammation involved in prostate carcinogenesis. Among genetic factors, 'genetic modifier alleles' of inflammatory genes show significant associations with PC risk, as described in the next section.
GENETIC POLYMORPHISMS THAT MODULATE INFLAMMATION AND PC ONSET AND PROGRESSION: THE ROLE OF 'GENETIC MODIFIER ALLELES'
Study of the human genome has enabled the dissection of complex human traits and has paved the way to understanding the basic pathways of health and disease. Population-based association studies have emerged as powerful tools for examining genes with a role in common multifactorial diseases that have a strong environmental component. These association studies often estimate the risk of developing a certain disease in carriers and non-carriers of a particular genetic polymorphism. The large majority of genetic variants studied are SNPs that occur with a frequency of 41% in the normal population (in contrast to 'mutations' that occur with a frequency of o1%). It is estimated that approximately 3.5 million SNPs are present in the human individual genome. 28 Naturally, most of these SNPs do not occur in coding sequences, and even those that do are not associated with any alteration in the amino-acid sequence and are therefore of no functional consequence. There has been an exponential increase in the number of published genetic association studies. Quite often, a report of a single genetic marker is published with great promise only to be followed by several negative studies that fail to reproduce the original observation. There is no doubt that the strategy of genetic association studies could be a powerful tool for dissecting human diseases, provided that certain principles are observed to minimize the chances of false-positive and -negative reports. 29 The emerging theme of the recent genetic association studies is the analysis of modifier genes. Interest in modifier genes is growing rapidly because of their ability to modify qualitatively and quantitatively the phenotype of another gene. Modifier genes have been shown to affect penetrance, dominance modification, progression, expressivity, pleiotropy and age of onset of monogenic and multigenic traits and diseases. Acting in a qualitative manner, a modifier may be required for a primary gene to express a phenotype. However, it appears that modifiers act more commonly in a quantitative manner. Modifiers may often underlie quantitative trait loci such that the summation of positive and negative modifier effects may greatly influence the resulting phenotype. This quantitative model explains how a disease allele may cause significantly different phenotypes. Each individual in an outbred human population possesses a unique complement of modifiers that influence the primary disease allele to produce variable phenotypic results. 30 A neglected class of modifiers are protective alleles that can suppress disease in otherwise susceptible individuals. Taken together, these modifier genes and protective alleles provide important glimpses into the molecular and cellular basis for the functional networks that provide robustness and homeostasis in complex biologic systems. 31 Furthermore, understanding the molecular and cellular basis by which modifier genes exert their influence might also provide insights into the identification of physiologic pathways as novel targets for therapeutic interventions in human diseases.
As briefly mentioned in the introduction, several modifier alleles in a large gene number of signaling pathways, including those involved in androgen action, DNA repair, carcinogen and sex steroid hormone metabolism and inflammation, have been identified to be associated with PC risk or to modulate it. Among these, some genetic modifier alleles of innate/inflammatory and sex hormone pathways have been examined in our studies and the data obtained are discussed in the next paragraph (see Tables 1  and 2 ).
In the following sections, we describe the role of genetic modifier alleles modulating inflammation and PC risk. Three genetic epidemiologic approaches (precisely the candidate gene approach, pathway analysis, and genome-wide association studies) have been used to assess SNPs of proinflammatory genes and PC risk. In addition, the number of studies reporting on the association between one or multiple SNPs in inflammation-related pathways, and thus PC risk, has greatly increased.
Candidate gene approach The candidate gene approach is a hypothesis-driven method that is widely used. Sequence variants of several inflammatory genes have been extensively explored to predict PC risk, 7, 19, 32 even if most of these findings are inconsistent. However, some interesting data have been obtained. Among these, an interesting association has been recently observed by Licastro et al. 33 between an SNP (GG genotype) in the promoter region of a-1-antichymotrypsin and increased risk for PC (age-adjusted odds ratio (OR) ¼ 2.676; confidence interval (CI): 1.375-5.205). a-1-Antichymotrypsin is an acute-phase protein upregulated in response to inflammation. a-1-Antichymotrypsin is also a serine protease inhibitor, and most circulating PSA is bound to ACT. 33 Another recent case-control study in the risk factors for prostate cancer study, by examining a cytokine-rich region at 5q31.1 implicated as suggested previously in PC risk, observed a modest association between two alleles of IL-4 and PC risk and no association between IL-5 or IL-13. 34 The associations with IL-4 were not present in another large case-control study (the Melbourne Collaborative Cohort Study). However, the authors evidence that one of the IL-4 alleles (rs2243250 genotype) led to a decrease in IL-4 activity, potentially pointing to an antitumor function of IL-4 in PC risk. 34 A number of recent studies have also detected the potential interaction of SNPs between multiple different cytokines in conferring an increased PC risk. Among these, the study of Zabaleta et al. 35 examined nine SNPs in three cytokines (IL-1B, IL-10 and TNF) in a case-control study of African-American versus Caucasian men. This study evidenced an increased combined risk of PC in African Americans carrying variants in IL-1B (IL1B-511CT/ TT) and IL-10 (IL10-592CC) (OR ¼ 2.56; 95% CI: 1.09-6.02). Similarly, in Caucasians, a higher risk for PC was associated with the combinations of variants of IL-1B (IL1B-31TT/TC) and IL-10 (IL10-1082AA) (OR ¼ 2.92; 95% CI: 1.13-7.55) as well as IL-10 (IL10-592AA) and TNF (TNF-238GG) (OR ¼ 2.14; 95% CI: 1.05-4.38). This same group also examined 15 SNPs in five cytokine genes (IL-1B, IL-10, TNF-a, IL-6 and IL-8) in relation to risk of aggressive PC (Gleason sum 8 or PSA 420 ng ml À 1 or Gleason sum 7 and clinical stages T3-T4) in African Americans and Caucasians. 33 Using the multivariate adaptive regression spline regression analysis, this study demonstrated an association between aggressive PC and an IL-8 (IL8-47CT) genotype (OR ¼ 3.50; 95% CI: 1.13-10.88) as well as an increased risk with combined genotypes in IL-1B (IL1B-511CC) and IL-10 (IL10-1082GG) (OR ¼ 3.38; 95% CI: 1.70-6.71) in Caucasian men. Unfortunately, the number of African-American men in this study was not large enough for analysis. Interestingly, both studies showed an association between increased risk for PC or aggressive PC. Another recent study investigated 143 SNPs in 16 inflammation-related genes (CXC ligand 12 (CXCL12), IL-4, IL-6, IL-6ST, prostaglandin-endoperoxide synthase 2 (PTGS2), signal transducer and activator of transcription 3 (STAT3), TNFa, protein kinase B (AKT1), CXCR4, IL-6R, IL-8, IL-10, NFkB, phosphatidylinositol Abbreviations: PC, prostate cancer; SNP, single-nucleotide polymorphism; TLR, Toll-like receptor.
SNPs of candidate genes in personalized cancer treatments CR Balistreri et al 3-kinase (PIK3)R1, PTGS1 and vascular endothelial growth factor (VEGF)) in a case-control study of African-American versus Caucasian men. 34 Among these SNPs, genetic variants in IL-4, IL-6ST, PTGS2 and STAT3 genes were associated significantly and independently with PC susceptibility. In addition, SNPs in AKT1, PIK3R1 and STAT3 were associated with aggressive PC. 36 These studies collectively underline the potential importance of the interactions between inflammatory cytokines and inflammation pathways in conferring PC risk.
Other inflammatory molecules seem to have a crucial role in PC. Among these, COX-2 (also known as PTGS2) is extensively studied with regard to PC. This enzyme is an inducible isoform of the enzymes that convert arachidonic acid to proinflammatory prostaglandins. An overexpression of COX-2 in PC has been observed, particularly in PIA areas. 7 Furthermore, several recently published studies have demonstrated significant associations of SNPs in the PTGS2 gene with PC risk. 7, 20, 37 However, different results have been obtained. 7, 20, 37 Nevertheless, COX-2 remains a molecule of particular interest in the link between inflammation and PC.
Of special note also are the data on the strong correlation between genetic variants of genes of the TLR4 pathway and PC susceptibility in humans. In particular, a large number of recent case-control studies performed in different populations of the world have examined the role of TLR4 SNPs in PC. 26 Accordingly, a large study analyzed eight TLR4 SNPs in 1383 PC patients and 780 age-matched controls from Sweden. It found that the sequence variant (11381G/C; rs11536889) in the 3 0 -untranslated region of the TLR4 gene increases PC risk by 4.9%. 38 In another large study, performed on 700 patients and 700 controls from the United States, 16 TLR4 SNPs have been analyzed. 39 Homozygosity for the variant alleles of eight SNPs has been associated with a statistically significant lower PC risk (TLR4_1893, TLR4_2032,  TLR4_2437, TLR4_7764, TLR4_11912, TLR4_16649, TLR4_17050 and TLR4_17923), while the TLR4_15844 polymorphism corresponding to 11381G/C was not associated with PC risk. 39 The findings of these previous studies were recently confirmed. Cheng et al., 40 analyzing six TLR4 SNPs in 1012 men, demonstrated that rs10759932 SNP was associated with a fourfold increased risk of disease.
Recently, we evaluated the role of þ 896A/G (Asp299Gly; rs4986790) and þ 1196 C/T (Thr399Ile; rs4986791) TLR4 SNPs in PC in the Sicilian population. A significant increase in þ 896A proinflammatory allele frequency was observed in PC patients when compared with age-related controls and centenarians (as described above), emphasizing the role of TLR4 in the pathophysiology of this age-related cancer. 41 To confirm our suggestions on the biologic effects of þ 896A/G TLR4 SNP in the pathophysiology 
Located within exon 1, the SNP consists of a G-to-A change in the third position of codon 211. The A allele associated with a statistically significant nearly threefold increased risk of PC among African-American men (age o65 years), likewise an excess proportion of this allele has been found among PC cases with an affected brother. European studies have also observed an association between A allele and high-grade disease Androgen sex hormone receptor pathway 59, 60 SRD5A2
A49T, rs9282858 A49T SNP substitutes threonine for alanine at codon 49; the T allele has been reported to be the allele with higher enzyme activity. It has been associated with a higher risk of PC Androgen sex hormone pathway (5-a-reductase enzyme) 59, 60 V89L, rs523349 V89L SNP substitutes leucine for valine at codon 89; it has been reported to reduce almost 30% of adrostanediol glucuronide, a serum marker of 5-areductase activity among Asians. Among Caucasian men, a 10% insignificantly lower androstanediol glucuronide level has been observed in individuals with the L/L genotype. Hence, V89L might reduce the risk for PC
It is a silent SNP in exon 10, corresponding to the 3 0 -untranslated region of mRNA; it has been proposed as functionally relevant, because it is correlated to the level of aromatase mRNA in tumor cells Androgen sex hormone pathway (aromatase enzyme) 59, 60 39Trp/Arg, rs2236722 Located in the codon 39 Trp/Arg, it is significantly associated with PC Arg264Cys, rs700519
Located in exon 7, it determines the C to T substitution in the position of nucleotide 826, resulting in the substitution from Arg to CYs at codon 264. It has been associated with an increased risk of PC ERa, ESR1 A351G, rs: 9340799 T397C, rs: 2234693 351A/G (or XbaI) and 397T/C (or PvuII), most widely studied SNPs of ER1 gene, seem to be in linkage disequilibrium. They have been associated with higher risk of PC. Concerning the XbaI SNP, higher circulating levels of androstenedione have been observed in A/A (or x/x genotype) The polymorphism IVS1-397 was described as a C-to-T change in the intron of ESR (located at position 397 before exon 2; http://genome.ucsc.edu). The substitution of T generates a sequence, which can be cut by ESR1 IVS1-397 T/C (PvuII) (CAG/CTG-complementary strand). This SNP has been associated with estrogen-dependent diseases. The clinical data indicate that carriage of this SNP has functional consequences by influencing ESR ligand binding and local estrogenic action
Estrogen sex hormonea receptor pathway 59, 60 ERb, ESR2 G1082A (no rs available designation)
It has been reported to be associated with increased estrogen dysfunction Estrogen sex hormoneb receptor pathway 59, 60 Abbreviations: ESR, estrogen receptor; PC, prostate cancer; SNP, single-nucleotide polymorphism; TLR, Toll-like receptor.
SNPs of candidate genes in personalized cancer treatments CR Balistreri et al
of PC, we recently assessed the levels of IL-6,TNF-a, IL-10 and eicosanoids in lipopolysaccharide-stimulated whole-blood samples from 50 young healthy Sicilians, screened for the presence of this SNP. Both proinflammatory cytokines and eicosanoids were significantly higher in carriers bearing the þ 896A TLR4 allele, whereas the anti-inflammatory IL-10 values were higher in carriers of the þ 896 G TLR4 allele. 42 This suggests the ability of the þ 896 G TLR4 allele to mediate a better control of inflammatory responses induced by chronic stimuli, likely decreasing the effects of prostate carcinogens.
Of the other TLR4-related pathway genes, only some SNPs of CD14 and NF-KB1 (encoding for the p50 subunit of NF-kB) genes have been analyzed to evidence their ability to modulate PC risk. 43, 44 In particular, the CD14 ( À 260C4T) polymorphism, located near the Sp1 transcription factor binding site and known to have a major influence on CD14 expression, has been demonstrated to be associated with PC in old African-American men in a study including 264 cases and 188 controls. 43 Furthermore, a functional insertion/deletion polymorphism (e94 insertion/deletion ATTG) in the promoter of the NF-KB1 gene has also been genotyped in a total of 117 PC patients and 143 control subjects. The frequency of the ATTG2 allele in PC patients was significantly higher than in controls (63.7% vs 54.5%; P ¼ 0.035, OR ¼ 1.461). Thus, the functional NF-KB1 promoter polymorphism seems to be associated with increased risk for PC. 44 Further investigations are certainly needed to explain the biologic mechanism of the TLR4 pathway in PC. However, it seems plausible from the current literature data that modifying the genetic sequence of the TLR4 gene could result in a high state of TLR4 activation, favoring chronic inflammation and carcinogenesis. On the other hand, an overexpression of TLR4 and endogenous TLR4 ligands has been observed in PC cells. 24 However, TLR4 engagement by endotoxin and by endogenous ligands represents a notable contribution to the outcome of different cancer treatments, such as radiation or chemotherapy. Further research on the role and mechanisms of TLR4 pathway activation in PC may provide novel antitumor vaccine adjuvants and TLR4 inhibitors that could prevent inflammation-induced PC carcinogenesis.
Pathway analysis
The pathway analysis approach, which is also hypothesis driven, relies on examining a more comprehensive set of genes involved in a specific functional role-for example, inflammation, cell cycle, DNA repair and so on. However, this approach is being overtaken by advances in high-throughput genome technology and the advent of genome-wide association studies. A case-control study used the multiple-stage design to analyze association between SNPs of over a thousand inflammatory genes and the risk for PC. Three SNPs, rs7250623 on the CRLF1 gene, rs753733 on the FCER2 gene (encoding the low-affinity receptor for immunoglobulin E (FceRII, CD23)) and rs2144493 on CIDEB (codifying cell deathinducing DFFA-like effector b) and LTB4R2 (encoding leukotriene B4 receptor 2) genes, are associated with PC risk. 45 Thus, pathway analysis enables us to investigate the subpathway interactions. However, it limits the ability to detect the crosstalk between the inflammation pathway and other pathways.
Genome-wide association study In the post-genome era, a genome-wide association study has become a powerful tool for analyzing the whole genome and identifying SNPs related to the outcome of interest.
Several genome-wide association studies in diverse ethnic groups have recently identified more than 40 germline variants of various genes or chromosomal loci that are significantly associated with PC susceptibility, including multiple 8q24 loci, prostate-specific genes, metabolic-and hormone-related genes and many regions where no coding gene is annotated. However, there are only a few variants or genes for which biologic significance or functions have been elucidated so far. The greatest challenge related to genome-wide association studies-associated loci in prostate genomics is to understand the functional consequences of these PC-associated loci and their involvement in PC biology and carcinogenesis. There have been attempts to determine PC risk estimations by combining multiple PCassociated variants for clinical tests, and these can identify a very minor population with a high risk for PC. However, they cannot distinguish the risk for aggressive PC from that for non-aggressive PC. Further identification of PC-susceptibility loci in larger genome-wide association study cohorts and biologic insights gained from such functional analyses have the potential to translate into clinical benefits, including the development of reliable biomarkers, risk estimation and effective strategies for screening and prevention of PC. 32 
SEX STEROID HORMONE-RELATED PATHWAYS IN PC
Sex steroid hormones are assumed to have a critical role in the complex pathophysiology of human PC. 7, [46] [47] [48] [49] Androgens are primarily responsible for the development and function of the human prostate gland as well as for the maintenance of homeostasis of prostate tissues in adulthood. The major prostatic androgen is testosterone and its derivative di-hydrotestosterone (DHT), produced locally through the 5a-reductase enzyme. Most of their effects are mediated by binding to androgen receptors (AR). Androgens also represent well-established risk factors for development and progression of benign and malignant disorders of the prostate gland. 46 Current evidence also suggests a crucial role of estrogens in both normal and diseased human prostate. [47] [48] [49] In particular, it hypothesizes that a combined action of androgens and estrogens and their balance seems to be remarkable in maintaining prostate health and tissue homeostasis. An alteration of this balance has been evidenced to be involved in the development of both benign and malignant diseases, including PC. 47, 48 In aging men, circulating levels of estradiol are unchanged or increased, as opposed to the decline of plasmatic testosterone. Estrogen production is maintained through aromatization of adrenal androgens driven by the aromatase enzyme, especially in peripheral adipose tissue. 47 In normal prostate gland, the aromatase enzyme is expressed within the stroma, while the malignant prostate shows an aberrant aromatase expression in the epithelial compartment. 46 This has been associated with an increased risk for PC. 48 This condition is further complicated by the differential expression and activity of the two estrogen receptors (ER), a and b. 46, 47 A sustained activation of ERa may eventually lead to an aberrant proliferation, inflammation and to the development of premalignant lesions. In contrast, ERb receptors have antiproliferative effects and exert a protective role against prostate carcinogenesis. 46, 47, 49, 50 Despite the above evidence, many epidemiologic studies have failed to show a significant association between circulating sex steroids and PC risk. [51] [52] [53] Indeed, several problems related to measurement of plasma steroids, both androgens and estrogens, should be considered to explain this large inconsistency in data. However, the ethnic variability and the heterogeneity of the genetic background among the individuals may well have a major impact. In particular, SNPs of genes involved in both metabolism and action of steroid hormones seem to be primarily implicated.
In the following paragraph, we describe the recent data on the role of genetic modifier alleles in sex hormone pathways in PC risk, by considering the candidate gene approach, pathway analysis and genome-wide association studies.
FOCUS ON THE ROLE OF GENETIC VARIANTS OF THE SEX HORMONE PATHWAY
Candidate gene approach The major chunk of literature on genetic studies on PC cancer has applied a candidate gene approach and examined genetic variations involved in sex hormone pathways. This strategy is based on pathophysiologic observations, such as varying rates of prostate tissue proliferation in response to changes in plasma or intraprostatic sex hormone levels, caused by genetic variations. The AR gene, the steroid a-reductase type 2 gene (SRDAR2, which converts testosterone to dihydrotestosterone in the prostate gland), the cytochrome P450c17 and P450c19 genes (CYP17 and CYP19, respectively, which are involved in the synthesis and degradation of sex hormones) and the ERa and ERb genes (ESR1 and ESR2, respectively) have all been studied extensively. Significant associations between some SNPs of these genes and PC risk have been observed. [54] [55] [56] [57] [58] However, most studies have been small and results have varied between men from different ethnic backgrounds. We have recently analyzed the association between PC and nine functional SNPs of the AR, SRD5A2, CYP19, ERS1 and ERS2 genes involved in sex hormone pathways (see Table 2 ). Our results suggested the potential association of seven out of nine SNPs with PC. [59] [60] [61] Genome-wide association studies As a result of developments in genotyping and data analysis over the past few years, genome-wide association studies have discovered new genetic variants and loci associated with PC incidence. 62 Pathologic implications of genetic variants of sex hormone pathway However, the mechanisms underpinning the putative role of PC risk-associated genetic factors in the development and/or progression of PC during the aging process remain unknown. Further studies are needed to confirm these data to get insight into relevant mechanisms, with special emphasis on the local metabolism and action of androgens or estrogens. It should be noted that circulating sex steroids cannot be considered representative of their intraprostatic levels, which strictly depend on the expression and activity of key enzymes governing local metabolism and biotransformation. 49 In this respect, the appraisal of steroid enzymes (such as aromatase and 5-a-reductase) and receptors (such as AR, ERa and ERb) that determine metabolic profiles and signaling, respectively, in both normal and diseased human prostate is crucially important to associate sex hormonerelated pathways and PC risk.
EMERGING DATA ON THE ROLE OF MICRORNA AND THEIR VARIANTS IN PC RISK: THEIR POTENTIAL ROLE AS NOVEL PC BIOMARKERS
MicroRNAs (miRNAs) are small noncoding RNAs that take part in post-transcriptional regulation either by arresting the translation or by cleavage (degradation) of mRNA targets. MiRNA regulation is performed by pairing the miRNA to sites in the messenger RNA of protein coding genes. miRNAs have been thought to be involved in many biologic processes (i.e. cell proliferation, death and differentiation) and are believed to regulate the expression of approximately one-third of all human genes. Mature miRNAs bind to their target mRNAs by complete or incomplete complementation of their 50-end nucleotides 1-8 (seed sequences) with a binding site in the 30-or 50-untranslated regions of target transcripts or in the coding sequences. This process results in direct cleavage of the targeted mRNAs or inhibition of translation. Currently, nearly 1700 human miRNAs have been identified. [63] [64] [65] In recent years, miRNAs have emerged as possible diagnostic and prognostic biomarkers that may stratify prostate tumors based on specific genetic profiles and thereby improve aspects of patient management, such as staging and treatment. [63] [64] [65] Although many cancer drugs poorly distinguish between cancer and normal cells, development of more precise and specific ways to recognize tumor cells would be of vital importance. The use of such genetic markers can create a unique new niche for the development of molecularly based drugs that can move PC research closer to personalized medicine and complement the current standard of care. [63] [64] [65] On the other hand, it has already been shown that miRNAs are aberrantly expressed in PC. In androgen-dependent andindependent PC cell lines, a differential expression of miR-148a has been found. MiR-125b expression has been reported to be increased in benign prostate lines compared with PC lines, and androgen receptor-positive cell lines expressed more miR-125b than androgen receptor-negative cell lines. [63] [64] [65] Furthermore, recent data have also evidenced a relatively small number of miRNAs involved in regulating inflammation in normal and pathologic aging. They are represented by miR-155, miR-21 and miR-146a, which are able to target particularly the TLR/NF-kB pathway, and named inflamma-miRs. In physiologic conditions, transcription of miR-155, miR-21 and miR-146a is at baseline levels. 66, 67 In contrast, the activation of proinflammatory TLR signaling immediately determines a strong induction of their expression through an NF-kB-dependent mechanism. 66, 67 These observations lead to the hypothesis that tissue and circulating inflamma-miRs may contribute to regulating the activation of the inflammatory network and the consequent release of the so-called senescence-associated secretory phenotype (represented by a myriad of factors, i.e. proinflammatory mediators). 17, 66, 67 In addition, they could be used to verify the damage induced by activation of the inflammatory response. 17, 66, 67 Inflamma-miRs have been implicated in the regulation of the immune and inflammatory response, and their abnormal expression may contribute to the low-level chronic inflammation 17, 66, 67 that has been documented both in normal aging and in the major age-related diseases such as PC. In particular, circulating inflamma-miRs could have diagnostic/ prognostic relevance in human diseases, such as PC, which share a common inflammatory background. 66, 67 Furthermore, recent evidence suggests that their activity and the expression of the miRNA targets are modulated by genetic variants in their sequence. Accordingly, two recent studies have underlined the association of SNPs, located at miRNA-binding sites (miRNA-binding SNPs) and likely able to affect the expression of the miRNA targets, with PC risk. 68, 69 In particular, George et al., 68 by genotyping a North Indian population constituted by 159 PC patients and 230 matched controls for hsa-mir196a2 (rs11614913), hsa-mir146a (rs2910164) and hsa-mir499 (rs3746444) SNPs, observed that patients with a heterozygous genotype in hsamir196a2 and hsa-mir499 showed significant risk for developing PC (P ¼ 0.01, OR ¼ 1.70 and Pp0.001, OR ¼ 2.27, respectively). Similarly, the variant allele carrier was also associated with PC (P ¼ 0.01, OR ¼ 1.66 and Pp0.001, OR ¼ 1.97, respectively), whereas hsa-mir146a revealed no association with PC. None of the miRNA polymorphisms were associated with Gleason grade and bone metastasis. Thus, combined genotypes of miRNA-related variants may be used to predict the PC risk and may be useful for identifying patients at high risk. 68 Another group of researchers analyzed the association between the G4C polymorphism (rs2910164) of miR-146a (located in the sequence of miR-146a precursor, and resulting in a change from a G:U pair to a C:U mismatch in its stem region) and PC risk and the expression of miR-146a with different genotypes in PC tissues in the southern Chinese Han population. 69 A total of 251 PC and 280 control subjects were included in this study, and 15 PC tissue samples were used to test the expression of the miRNA precursors by realtime quantitative reverse transcription-polymerase chain reaction.
They observed that subjects carrying CC homozygotes had a 0.65-fold reduced risk (95% CI ¼ 0.43-0.99) compared with those carrying GG/GC genotypes (P ¼ 0.03), and the C allele displayed a lower prevalence of PC compared with the G allele (OR ¼ 0.73, 95% CI ¼ 0.57-0.94, P ¼ 0.01). Moreover, hsa-miR-146a quantification showed that homozygous carriers of the C variant had significantly decreased miRNA levels compared with carriers of the GG/GC genotype. Thus, the natural genetic variation in pre-miR146a affects the amount of mature miR-146a and contributes to the genetic PC predisposition. 69 These data suggest miRNA and their SNPs as novel PC risk biomarkers, although further studies are certainly indispensable.
OUR HYPOTHESIS: INTERPLAY BETWEEN SEX STEROID AND IMMUNE INFLAMMATORY NETWORK AND DETECTION OF A GENETIC RISK PC PROFILE BY USING AN ALTERNATIVE APPROACH
Considering our expertise in age-related inflammatory diseases, we hypothesize that a complex endocrine-inflammatory immune interaction is primarily implicated in human PC pathophysiology. In this framework, the major goal of our recent studies 7, 41, [59] [60] [61] was to analyze the role of modifier SNPs in genes, codifying molecules involved in inflammatory and sex steroid pathways (see Tables 1 and 2 ), as described above, in PC risk. In addition, it also sought to identify a genetic risk profile. The detection of a risk profile potentially allows both the early identification of individuals at risk for disease and the possible discovery of potential targets for medication. On the other hand, the major interest of current research is to improve early detection of age-related diseases, cancer included, by developing tools to move diagnosis backward in disease temporal course-that is, before the clinical manifestation of the malady. Indeed, in this preclinical phase the treatment might have a decisive role in preventing or significantly retarding the disease manifestation. The better understanding of the function and regulation of the inflammatory/sex steroid pathways in PC may help identify the mechanisms of its onset and progression, as well as detect new targets for the refinement of new treatment such as the pharmacogenomics approach.
In achieving this purpose, we used in our association genetic studies a particular approach, characterized by analyzing an additional control group represented by centenarians (as mentioned above), 'exceptional individuals' able to avoid major common age-related diseases, including cancer. 41, [59] [60] [61] This kind of approach has been named 'positive biology', as it seeks to understand the causes of positive phenotypes, trying to explain the biologic mechanisms of health and well-being. 70 As described in the study by Balistreri et al., 41 we identified a risk profile in PC patients when compared with centenarians. In particular, we detected an overexpression of a proinflammatory genetic risk profile in PC patients with respect to centenarians
high proinflammatory genotype (36% versus 11%, P ¼ 0.002; OR ¼ 4.59, CI: 1.6-12.8, P ¼ 0.004). In addition, analyzing the association between PC risk and nine functional SNPs of the AR, SRD5A2, CYP19, ERS1 and ERS2 genes involved in sex hormone pathways, we observed that seven out of nine SNPs were associated with PC risk. Most of the selected alleles were also under-represented in centenarians. 59 All together, these data lead one to hypothesize that the genetic background promoting proinflammatory responses may have opposite roles in PC and longevity. On the other hand, we have previously demonstrated that alleles associated with agerelated diseases are not included in the genetic profile favoring longevity. 61, 71, 72 Accordingly, the SNPs selected in our PC studies seem to function in an antagonistically pleiotropic manner. They exert a beneficial role in younger age, maintaining the physiologic growth and homeostasis of the prostate gland. In contrast, in old age they have a detrimental role, inducing aberrant cell proliferation and inflammation and being involved in the development of benign and malignant lesions.
Furthermore, our findings lead us to suggest possible therapeutic treatments in subjects with severe risk factors for PC. For example, we propose in subjects with 'high-risk' alleles of the PTGS2 and 5-lypoxygenase genes the possibility of developing preventive measures using specific inhibitors of eicosanoids and/ or their enzymes. In people who do not respond to (or comply with) nonsteroidal anti-inflammatory drug therapy, other more sophisticated preventive approaches have been proposed, including the use of agonists of TLR receptors in subjects who are carriers of þ 896A/G TLR4 and þ 2408 G/A TLR2 SNPs. The aim of such an approach would be to block the TLR-NF-kB signaling pathway required for induction of inflammatory responses and the release of proinflammatory mediators. This approach might reduce the risk of PC development. 7, 41, [59] [60] [61] Another possible therapeutic intervention in subjects with proinflammatory alleles of TLR4 and TLR2 genes might be antibody-mediated stimulation of TAM receptors involved in the inhibition of the inflammatory response. The sequential induction of this pathway and its integration with upstream TLR and cytokine signaling networks may limit the inflammatory response and maintain innate immune system homeostasis. A better understanding of the regulatory mechanisms of this cascade may have important implications for therapeutic intervention in human immune disorders. 41 
CONCLUSIONS AND FUTURE PERSPECTIVES: TRANSLATION OF PATHOLOGIC IMPLICATIONS IN PERSONALIZED CANCER MEDICINE
The combination of genetic tools and clinical information with respect to a specific cancer, such as PC, is giving new focus to medicine by way of 'personalized cancer medicine'. 73, 74 'Personalized oncology' includes the concept that each individual solid tumor and hematologic malignancy in each person is unique in cause, rate of progression and responsiveness to surgery, chemotherapy and radiation therapy'. This paradigm shift requires the identification of new validated biomarkers. In the next decade, oncology will move from a reactive to a proactive discipline-a discipline that is predictive, personalized, preventive and participatory. In addition, tools for implementing pre-emptive medicine based on genetic and molecular diagnostics and interventions will emerge and these will improve prevention, early detection and access to care. Health-care oncology professionals need to keep themselves informed of new tumor biomarkers, their optimal clinical use and the management of side effects.
In the specific case of PC, this new goal might lead to replacement of the instruments for detecting PC cancer with new and more specific biomarkers. In addition, it might also improve the efficiency of genetic tools and new-generation sequencing technologies for PC prevention of individuals carrying inflammatory and sex steroid pathway polymorphisms and their relatives. Accordingly, these new approaches will offer the possibility of earlier detection of the pathology and a different or specific treatment strategy depending on an individual's genotypes. Use of genetic biomarkers, such as polymorphisms of inflammatory genes or genetic variants of genes codifying molecules of sex steroid hormone pathways, may also enable one to stratify patients on the basis of the aggressiveness of the pathology. This approach might provide signatures on inflammatory and sex steroid tissue status and help in selecting suitable patients to evaluate target modulation.
In addition, SNPs may operate in combination to create a 'risk profile' and modify the effectiveness of disease therapies. Combinations of several inflammatory and sex steroid hormone pathway SNPs are found in PC patients, as mentioned above. Thus, their combinations might be used as markers in a pre-and post-treatment clinical PC setting. Accordingly, their identification may hold promise for the realization of personalized PC medicines (Figure 2) . Indeed, it might be useful to guide treatment choice in men with newly diagnosed PC, distinguishing low-risk from highrisk disease through the identification of a risk profile. This approach might provide more appropriate data on prognostic impact than those usually obtained using histology-based Gleason score. However, it is still being tested and adding to studies based on transcriptome analysis.
The combination of this information will allow medical professionals to establish different medical protocols in more aggressive PC types and offer the possibility of performing preliminary controls in families considered at risk. Although many significant steps in the treatment of PC have been taken with respect to clinical matters and genetic information, there is still a long way to go.
In any case, the creation of a personalized panel of SNP biomarkers for PC and for a specific cancer may be important for its early and accurate detection. On the other hand, PC is characterized by being extremely difficult to diagnose and treat, as it can take decades to progress to a clinically manifest state. As a consequence, the necessity for a good biomarker is required to detect PC earlier and to provide tools to follow up patients during the early stages of the cancer.
At present, PC continues to have an unclear etiology, which is a combination of genetic and numerous environmental factors and hormonal imbalance. Furthermore, several studies have shown that risk profiles based on known common susceptibility alleles have limited discriminatory power for PC, 75 leading some investigators to conclude that the clinical utility of risk prediction based on polygenic profiling is still limited. However, discrimination is not the only measure of clinical utility of a risk prediction model, and it has been suggested that polygenic risk profiling may provide sufficient information to enable screening for PC cancer to be targeted to those men at highest risk; 76, 77 however, evidence from empirical data is needed. Nevertheless, this approach has the potential to inform public health policy decision making in the context of population screening. Figure 2 . Genetic analysis and clinical information permit the identification of a 'risk genetic profile' represented by a combination of inflammatory and sex steroid hormone pathway single-nucleotide polymorphisms (SNPs). They can represent optimal prostate cancer (PC) biomarkers, useful in improving the efficacy of PC early detention/prevention. At the same time, they might be used as optimal new drug therapeutic targets. In addition, this may lead and guide, versus a preferential treatment, the personalized treatment depending on the individual's genotypes.
